Research Peptides Explained — the complete 2026 reference guide

Type “BPC-157” into a search bar and you will find it described, in the same afternoon, as a miracle, a scam, and a stomach peptide nobody has properly tested in humans. All three claims circulate with equal confidence. The problem is not that research peptides are mysterious — their sequences are public and their chemistry is routine — but that the field has no shared map. This guide supplies one.

What actually is a “research peptide”?

A peptide is a short chain of amino acids — conventionally fewer than about fifty — joined by the same bonds that build proteins, but small enough to synthesise to a defined sequence in a laboratory rather than express in cells.³⁴ “Research peptide” is therefore not a pharmacological category at all; it is a supply category. It denotes a synthetic, sequence-defined compound supplied strictly as a Research-Use-Only (RUO) reference material — a characterised sample for in-vitro and animal experimentation — and explicitly not a medicine, a supplement, or anything intended for administration to a person.

That distinction matters more than it first appears. A few of the sequences below are also the active ingredients of licensed drugs. When that is true, the approved medicine and the research-grade material are two different things on two different regulatory tracks,⁹ and the existence of one tells you almost nothing reliable about the other.

How is the field classified?

The useful axis is biological target. Peptides that hit the same receptor system tend to share mechanisms, evidence quality and open questions,²⁷ so a researcher who knows the class already knows most of what to ask. Eight families cover the bulk of the catalogue.

A working taxonomy of the research-peptide field by target class, with representative compounds and the honest evidence tier for each. Approval status refers to licensed medicines built on the sequence, not to research-grade material.

Read the table as a topology, not a league table. Two compounds in the same row can sit at opposite ends of the evidence spectrum: tesamorelin is a GH secretagogue with regulatory approval, while CJC-1295 in its sustained-action form has been the subject of comparatively little controlled human study.⁸ The class tells you the mechanism; it does not tell you the evidence.

How are they made and characterised?

Almost all are built by solid-phase peptide synthesis (SPPS): the chain is assembled one protected amino acid at a time on an insoluble resin, then cleaved and deprotected.³¹¹ The method was introduced by Bruce Merrifield in a 1963 paper, work for which he later received the 1984 Nobel Prize in Chemistry. SPPS is reliable and scalable, but each coupling step is imperfect, so the crude product is a mixture of the target sequence and closely related impurities — deletion sequences, truncations, incomplete deprotections.⁶

Characterisation is therefore the whole job. Reversed-phase high-performance liquid chromatography (HPLC) separates and quantifies those impurities, giving a purity figure — commonly reported as a percentage of total peak area.⁶ Mass spectrometry confirms identity by measuring the molecular mass against the theoretical value for the sequence, catching errors HPLC alone would miss.¹ The per-lot Certificate of Analysis (COA) is where these results live: it is the document that converts a vial of white powder into a defined reference material.

95%+ the purity specification frequently quoted for research-grade peptide reference material — though the figure is meaningless without the chromatogram and mass-spec data behind it.

What does the evidence actually say?

Here is the spine of the whole field, and the part the marketing buries. The evidence behind research peptides is a spectrum running across four tiers, and most compounds sit far from the prestigious end.⁹¹²

At the top, a small number are approved medicines. Semaglutide and tirzepatide are licensed for type-2 diabetes and obesity on the strength of large randomised trials.²⁵ Tesamorelin is approved for HIV-associated lipodystrophy, afamelanotide for erythropoietic protoporphyria (a rare light-sensitivity disorder), and bremelanotide (PT-141) for a specific sexual-dysfunction indication. Below them sit compounds with genuine but limited clinical data — retatrutide, for instance, has reached advanced human trials but is not yet approved.⁷ Then comes the largest tier by far: preclinical-only compounds whose entire reputation rests on animal and in-vitro work. BPC-157, the field’s poster child, has produced striking results in rodent models but has essentially no controlled human evidence.⁹ Epitalon and the broader Khavinson bioregulator literature sit largely with a single research group.

The honest position is not that research peptides are worthless or miraculous, but that the field spans approved drugs and animal-only curiosities⁷⁸ — and the grey market sells every one of them as though it were the former.

That last clause is the real hazard. A vendor describing a preclinical rodent peptide in the cadence of an approved therapeutic is not lying about chemistry; the sequence is real. They are lying about evidence, collapsing four tiers into one. For a researcher, the discipline is to keep the tiers separate and to treat in-vitro promise as a hypothesis, not a result.¹²

Why is provenance the whole game?

If you accept that these are reference materials rather than products with claims, the quality question reframes itself. What you are buying is not an effect — it is a known quantity of a known molecule. That makes provenance everything. Two vials labelled identically can differ in purity, in counter-ion content, in the specific impurity profile SPPS left behind,⁶¹¹ and only the COA distinguishes them. Reports on grey-market peptides have repeatedly described mislabelling, under-filling and contamination,¹⁰ which is precisely what a per-lot certificate exists to expose.

Everything supplied here is a Research-Use-Only reference material, intended solely for in-vitro and laboratory research and not for human or veterinary use, diagnostic application, or any form of administration. Vialled powders and capsule formats are laboratory sample presentations, not preparations for dosing. Each lot ships with a Certificate of Analysis reporting HPLC purity and mass-spectrometric identity,⁴ because in a field this crowded with overstatement, a verifiable chromatogram is worth more than any claim — and is the only honest basis on which a serious researcher should choose a supplier.